Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference20 articles.
1. Bioresearch Monitoring Program Information (BIMO) Inspections Metrics. Available from https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/bimo-inspection-metrics. Updated Sept 29th, 2022. Retrieved October 28th, 2022.
2. US Food and Drug Administration. Inspections, compliance, enforcement, and criminal investigations: enforcement actions, warning letters. Available from https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters Updated Oct 26th, 2022.
3. Koneswarakantha B, Ménard T, Rolo D, et al. Harnessing the power of quality assurance data: Can we use statistical modeling for quality risk assessment of clinical trials? Ther Innov Regul Sci. 2020;54:1227–35. https://doi.org/10.1007/s43441-020-00147-x.
4. Getz KA, Campo RA. New benchmarks characterizing growth in protocol design complexity. Ther Innov Regul Sci. 2018;52(1):22–8. https://doi.org/10.1177/2168479017713039.
5. Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther. 2008;15(5):450–7. https://doi.org/10.1097/MJT.0b013e31816b9027.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献